Study Phase 3

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women (INGABO)

Trial Information

Generic NameAd26.ZEBOV and MVA-BN-FiloProduct NameZabdeno and MvabeaTherapeutic AreaAnti-Infectives for Systemic UseProduct ClassVaccinesPharmacological SubgroupViral VaccinesChemical SubgroupOther Viral VaccinesCondition StudiedEbola
Sponsor Protocol NumberVAC52150EBL3010Enrollment4031Data PartnerJohnson & Johnson% Female100%Mean/Median Age (Years)26.0% White0.0%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.